Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1915
Title: A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial
Authors: Chan, Matthew M K ;Davidson, A.;Veillard, A.S.;Hughes, B.G.;Boyer, M.;Briscoe, K.;Begbie, S.;Abdi, E.;Crombie, C.;Long, J.;Boyce, A.;Lewis, C.R.;Varma, S.;Broad, A.;Muljadi, N.;Chinchen, S.;Espinoza, D.;Coskinas, X.;Pavlakis, N.;Millward, M.;Stockler, M.R.
Issue Date: Nov-2015
Source: Volume 26, Issue 11, pp. 2280-2286
Journal title: Annals of Oncology
Abstract: BACKGROUND: We sought to determine whether the substantial benefits of topical nitroglycerin with first-line, platinum-based, doublet chemotherapy in advanced nonsmall-cell lung cancer (NSCLC) seen in a phase II trial could be corroborated in a rigorous, multicenter, phase III trial. PATIENTS AND METHODS: Patients starting one of five, prespecified, platinum-based doublets as first-line chemotherapy for advanced NSCLC were randomly allocated treatment with or without nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after, each chemotherapy infusion. Progression-free survival (PFS) was the primary end point. RESULTS: Accrual was stopped after the first interim analysis of 270 events. Chemotherapy was predominantly with carboplatin and gemcitabine (79%) or carboplatin and paclitaxel (18%). The final analysis included 345 events in 372 participants with a median follow-up of 33 months. Topical nitroglycerin had no demonstrable effect on PFS [median 5.0 versus 4.8 months, hazard ratio (HR) = 1.07, 95% confidence interval (CI) 0.86-1.32, P = 0.55], overall survival (median 11.0 versus 10.3 months, HR = 0.99, 95% CI 0.79-1.24, P = 0.94), or objective tumor response (31% versus 30%, relative risk = 1.03, 95% CI 0.82-1.29, P = 0.81). Headache, hypotension, syncope, diarrhea, dizziness, and anorexia were more frequent in those allocated nitroglycerin. CONCLUSION: The addition of topical nitroglycerin to carboplatin-based, doublet chemotherapy in NSCLC had no demonstrable benefit and should not be used or pursued further. CLINICAL TRIALS NUMBER: Australian New Zealand Clinical Trials Registry Number ACTRN12608000588392.
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1915
DOI: 10.1093/annonc/mdv373
Pubmed: https://pubmed.ncbi.nlm.nih.gov/26347110/
ISSN: 0923-7534
Publicaton type: Journal Article
Keywords: Cancer
Study or Trial: Randomized Controlled Clinical Trial/Controlled Clinical Trial
Appears in Collections:Oncology / Cancer

Show full item record

Page view(s)

32
checked on Dec 26, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.